FDA Week - 10/04/2019

FDA Gets Congressional Go-Ahead To Revamp New Drug Review Office

By Beth Wang / September 26, 2019 at 5:44 PM
FDA’s plan to streamline its reviews of new drugs through a major reorganization effort has been approved by Congress, agency drug center director Janet Woodcock announced Thursday (Sept. 26). The agency will now move forward with its revamp of the Office of New Drugs (OND), Office of Translational Sciences (OTS) and Office of Pharmaceutical Quality (OPQ). The agency hopes to make drug reviews more effective and efficient by increasing the number of review divisions, each of which will specialize in...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.